Subcutaneous wound infiltration of ketamine is superior to bupivacaine in terms of pain perception and opioid consumption after cesarean section: a double-blinded randomized placebo-controlled clinical trial.

OBJECTIVE: The aim of the present study was to evaluate the analgesic efficiency of SC ketamine, either alone or in combination with bupivacaine, following CS by means of postoperative pain and opioid need. PATIENTS AND METHODS: One hundred and twenty women were allocated into 4 groups in this prospective, double-blind, placebo-controlled, randomized trial. Group K (Ketamine, n=30) received SC 1 mg/kg ketamine. Group B (Bupivacaine, n=30) received SC 20 mL bupivacaine 0.5%. Group KB (Ketamine+Bupivacaine, n=30) received SC ketamine 1 mg/kg plus SC 20 mL bupivacaine 0.5%. Group P (Placebo, n=30) received SC 30 mL 0.9% saline (placebo). RESULTS: VAS scores at resting and on coughing and analgesic consumptions were compared. Visual analogue scale (VAS) pain scores at rest and coughing, at 15 and 60 minutes, and 2, 6 and 12 hours, and total opioid necessity were measured. VAS scores at rest in Group P were higher than in Group KB at the 6th hour, while lower in Group K and Group KB than in Groups B or P at the 12th hour. Patients receiving placebo had higher coughing VAS scores than those receiving ketamine or ketamine+bupivacaine at 2nd, 6th and 12th hours. Patients in Groups P and B required higher doses of morphine than those in groups K or KB. CONCLUSIONS: Subcutaneous ketamine, either alone or in combination with bupivacaine, provides a better postoperative pain relief and reduces postoperative opioid consumption when compared to use of bupivacaine alone.

The comparison of intraincisional bupivacaine infiltration and intravenous paracetamol administration for pain alleviation after cesarean section: a double-blinded randomized placebo controlled clinical trial.

OBJECTIVE: This study aimed to compare the analgesic effect of subcutaneous (SC) bupivacaine and intravenous (IV) paracetamol on postoperative pain and opioid requisites in patients undergoing cesarean delivery. PATIENTS AND METHODS: One hundred and five women were allocated into 3 groups in this prospective, double-blind, placebo-controlled, randomized trial. Group 1 received SC bupivacaine, Group 2 received IV paracetamol following surgery and every 6 hours for 24 hours in the postoperative period, Group 3 received SC 0.9% saline and IV 0.9% saline at similar periods. Visual analogue scale (VAS) pain scores at rest and coughing, at 15 and 60 minutes, and 2, 6 and 12 hours, and total opioid necessity were measured. RESULTS: VAS scores at rest were higher in placebo group than in bupivacaine and paracetamol groups at 15 minutes (p=0.047) and 2 hours (p=0.004). VAS scores at coughing were higher in placebo group than in bupivacaine and paracetamol groups at 2 hour (p=0.001) and 6 hours (p=0.018). Placebo group needed higher (p<0.001) doses of morphine than paracetamol or bupivacaine groups. CONCLUSIONS: Intravenous paracetamol decreases pain scores similar to SC bupivacaine in the postoperative period compared to placebo. Patients taking bupivacaine or paracetamol need fewer opioids than placebo.

Disrupted redox balance in utero-placenteal junction may be the main culprit in the occurrence of abruptio placenta.

OBJECTIVE: To determine the oxidant/antioxidant balance and proinflammatory status in amniotic fluids collected during cesarean section of patients diagnosed with abruptio placenta. PATIENTS AND METHODS: Twenty-five patients diagnosed with ablatio placenta with intact membranes who went to emergency cesarean section were included in the study. A diagnosis of AP was made in those who had at least one of the following criteria or, in suspicious cases, two findings. (i) Antepartum hemorrhage starting after 20 weeks of gestation, (ii) presence of retroplacental hematoma on ultrasonography, (iii) severe fetal distress or death, (iv) localized or diffuse uterine tenderness or pain. The control group consisted of 25 patients who presented for delivery, who were not diagnosed with AP, and whose membranes were intact. NF-κB, total oxidant capacity (TOC), total antioxidant capacity (TAC), and oxidative stress index (TOC/TAC=OSI) levels were measured in amniotic fluids collected during cesarean section from both groups. RESULTS: Amniotic fluid TAS values of the AP group were significantly lower than the healthy controls (1.14±0.33 vs. 9.05.±3.40, p<0.01). Amniotic fluid TOS values were significantly increased in the AP group (36.1±8.10 vs. 11.4±2.77, p<0.02). OSI values were significantly higher in the AP group (31.6±9.03 vs. 1.26±0.02, p<0.01). Amniotic fluid NF-κB expression of the AP group was approximately 5 times higher than the control group (10.4±2.56 ng/mL vs. 1.86±0.30 ng/mL, p<0.01). High blood pressure and smoking history were significantly higher in the AP group. Gestational age and fetal birth weight of the AP group were lower than the control group. CONCLUSIONS: Since the increase in amniotic fluid oxidant capacity and proinflammatory cytokine synthesis cannot be neutralized by the antioxidant system, hypoxic cell damage may lead to premature separation of the placenta.

Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.

OBJECTIVE: Heterogeneous real-world evidence can complement the more strictly regulated clinical trial data. A benefit of this is the wide range of backgrounds, comorbidities and characteristics that can give additional insights into treatments. Observational, retrospective studies can help to fill in the mosaic that makes up a treatments landscape. Tildrakizumab, an interleukin 23p19 inhibitor, is approved for the treatment of plaque psoriasis and has been shown to be a safe and efficacious therapy in clinical trials and emerging real-world evidence. We aimed at confirming the efficacy of tildrakizumab in patients with plaque psoriasis in a dual center setting and identifying patients' characteristics leading to better treatment response. PATIENTS AND METHODS: Patients with moderate to severe plaque psoriasis, eligible for systemic biological treatment, and treated with tildrakizumab were included in the study and the routine clinical parameters - Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and safety - were retrospectively analyzed. RESULTS: The combined cohorts included 89 patients, of which 64% were naïve to biologic therapies. At the time of analysis efficacy assessment was available for 39 patients after 12 months of treatment, 73 patients after 36 weeks, 79 patients after 16 weeks and 82 patients after 4 weeks. PASI and DLQI decreased significantly over time, with 52/73 (71.2%) patients achieving PASI 100 after 36 weeks. No severe side-effects were recorded in association with tildrakizumab. CONCLUSIONS: We confirmed the safety and efficacy of tildrakizumab in a real-world clinical setting. A higher proportion of patients naïve to biologics achieved a greater PASI response than patients who had previously been treated with biologics. The same was true for older patients and patients with a shorter history of disease.

The Resolution Rate of Pulmonary Embolism on CT Pulmonary Angiography: a Prospective Study.

PURPOSE: To prospectively assess the rate of clot resolution from CT pulmonary angiography (CTPA) in patients with acute pulmonary embolism (PE). MATERIALS AND METHODS: This prospective cohort study included 290 patients (136 men, 154 women; mean age, 51.9 years) with acute PE. All patients had a CTPA at the presentation and had at least one follow-up within 6 months (mean 72.7 days). Sixty-four percent of patients had follow-up scans for research purposes within a pre-determined period (between 28 and 184 days; mean, 78.27 days) and 36 % had (between 2 and 184 days; mean, 62.78 days) for a clinical indication. The volume of each clot was measured using a semi-automated quantification program. The resolution rate was evaluated by interval-censored analysis. RESULTS: The overall estimated probability of complete resolution was 42 % at 7 days, 56 % at 10 days, and 71 % at 45 days. Achieving complete resolution was significantly faster in patients with peripheral clots (HR: 1.78; CI: 1.05-3.03, p = 0.032) but slower in patients with consolidation and history of venous thromboembolism (VTE), (HR: 0.37; CI: 0.18-0.79, p = 0.01 and HR: 0.57; CI: 0.35-0.91, p = 0.019, respectively). Although the patients with cancer showed a faster resolution rate (HR: 1.67; CI: 1.05-2.68, p = 0.032), the mortality rate was significantly higher than non-cancer patients. CONCLUSION: The resolution rate of clot burden in acute PE was associated with patients' clinical presentation variables and CTPA imaging biomarkers. This information may be incorporated into designing a prediction rule and determining the appropriate duration of anticoagulation therapy in patients with acute PE.

Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology.

Exponential technologic advancements in imaging, high-performance computing, and artificial intelligence, in addition to increasing access to vast amounts of diverse data, have revolutionized the role of imaging in medicine. Radiomics is defined as a high-throughput feature-extraction method that unlocks microscale quantitative data hidden within standard-of-care medical imaging. Radiogenomics is defined as the linkage between imaging and genomics information. Multiple radiomics and radiogenomics studies performed on conventional and advanced neuro-oncology image modalities show that they have the potential to differentiate pseudoprogression from true progression, classify tumor subgroups, and predict recurrence, survival, and mutation status with high accuracy. In this article, we outline the technical steps involved in radiomics and radiogenomics analyses with the use of artificial intelligence methods and review current applications in adult and pediatric neuro-oncology.

Imaging findings of a rare pararectal splenosis and literature review.

Pararectal splenosis is an extremely rare lesion caused by ectopic auto-transplantation of splenic tissue after splenic trauma or splenectomy. It is often asymptomatic and detected incidentally during radiologic evaluation. We present a 24-year-old male with pararectal splenosis. The patient had a history of splenectomy and presented with complaints of abdominal discomfort and chronic constipation. Contrast-enhanced computed tomography (CT) revealed multiple well-enhanced masses located in the abdominal cavity and one mass in pararectal area. Additionally, the pararectal lesion showed diffusion restriction on diffusion-weighted magnetic resonance imaging (DW-MRI). In this case report, we aim to highlight the significance of taking a detailed medical history; and using DW-MRI for diagnosis of splenosis by presenting a case in a rare location.

Pythagorean fuzzy VIKOR-based approach for safety risk assessment in mine industry.

INTRODUCTION: Underground mining is considered one of the most hazardous industries and is often associated with serious work-related fatalities; this paper addresses job-related hazards and associated risks. METHOD: A risk assessment approach is proposed (Pythagorean fuzzy environment) and a case study is carried out in an underground copper and zinc mine. RESULTS: Results of the study demonstrate that hazards can be categorized into different risk levels via compromised solutions of the fuzzy approach. CONCLUSION: The study provides a theoretical contribution by suggesting a Pythagorean fuzzy numbers-based VlseKriterijumska Optimizacija I Kompromisno Resenje (PFVIKOR) approach. Moreover, it contributes to improving overall safety levels of underground mining by considering and advising on the potential hazards of risk management. Practical applications: The proposed approach will improve the existing safety risk assessment mechanism in underground copper and zinc mining.

Comparison of EDCs removal in full and pilot scale membrane bioreactor plants: Effect of flux rate on EDCs removal in short SRT.

Currently, it is estimated that over 1 billion people are short of adequate portable water and this is expected to increase to 2.5 billion in the year 2025. Membrane Bioreactors (MBR) are now accepted as important tools to extend the availability of water by facilitating the reuse of wastewaters. Sludge Retention Time (SRT) and liquid flux rate are the two most important parameters for controlling the MBR process. In this study, the removal of selected endocrine disrupter compounds (EDCs), diltiazem, progesterone, estrone (E1), carbamazepine (Cbz) and acetaminophen (Acet), by one full scale (VRM) and one pilot scale (clear-box) MBR plants was investigated. During the study, sludge age was set at 10 days and the sludge concentration was fixed at about 5.0 g/L. The transmembrane pressure (TMP) got higher with either increasing flux or sludge concentration in the membrane chamber. Therefore, changing the flux from 13 to 30 L/m2-h in both plants caused enhancement in TMP from -25 to -300 mbar in the clear-box and from -160 to over -350 in the full scale MBRs. It was understood that flux had very little effect on the removal of EDCs at very low concentrations. Moreover, diltiazem was completely removed in the full scale whereas no removal was achieved in the pilot scale. Estrone and progesterone were completely removed by biodegradation in both plants. Acetaminophen was completely removed in the full scale plant whereas over 95% removal was achieved in the pilot scale MBR.